A Study to Learn About the Occurrence of ADHD in Adults With Mental Conditions and Their Quality of Life
NCT ID: NCT04943796
Last Updated: 2025-10-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
224 participants
OBSERVATIONAL
2023-11-06
2025-07-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevalence of Disruptive Behavior in Children With Attention Deficit Hyperactivity Disorder(ADHD)
NCT05070481
Adult Outcome of Children With Attention-deficit/Hyperactivity Disorder
NCT01247610
Integrated Diagnosis and Treatment of Adults With Attention-deficit/Hyperactivity Disorder
NCT01615679
Identification of Neuropsychological, Genetic and Neuroimaging Markers and Treatment Response Predictors of ADHD
NCT02430896
A Systematic Study of Assessment of Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT05588713
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part I: Participants with ADHD
Participants with psychiatric disorders undergoing ADHD diagnosis.
No interventions assigned to this group
Part II: Participants with ADHD
To collect pseudonymized data from participants who are underdiagnosed of ADHD with psychiatric disorders in daily clinical practice for up to 9 months from both Part I and II.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult greater than or equal to (\>=)18 years of age or Canadian adult \>=19 years of age
* Ability to consent, as judged by the study investigator
* Diagnosis of at least one psychiatric disorder of at least 12 months duration, based on International classification of diseases (ICD)-10 codes registered in electronic health records
* Consecutive assessment for ADHD (as per routine clinical practice)
* Able to read and write in the first language of the respective country
Part II
* Inclusion in study Part I
* Diagnosis of ADHD during Part I, according to routine diagnostic procedure and algorithms
* Anticipated availability for being followed over 9 months
Exclusion Criteria
* Diagnosis of any of the following at any time prior to signing informed consent: schizoaffective disorder, intellectual disability, or other cognitive disorders
* Occurrence of any of the following events within the 6 months prior to signing consent: psychotic episodes, acute intoxication, or psychotropic drug withdrawal syndrome.
* Diagnosis of ADHD at any time before study inclusion
* Serious and unstable medical condition (severe disease that limits survival to 1 year)
* Participation in a clinical interventional trial in the 12 months prior signing consent
Part II:
\- Participant being followed-up for ADHD in a different site
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Takeda
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pacific Coast Recovery Care
Burnaby, British Columbia, Canada
Hopital de Psychiatrie de Trois-Rivières, Pavillon St-Joseph
Trois-Rivières, Quebec, Canada
Regina Mental Wellness Clinic
Regina, Saskatchewan, Canada
Charité - Universitätsmedizin Berlin
Berlin, , Germany
Klinik und Poliklinik für Psychiatrie und Psychoterapie
Bonn, , Germany
Universitätsklinikum Frankfurt am Main
Frankfurt am Main, , Germany
Asklepios Klinikum Hamburg
Hamburg, , Germany
Hospital Vall d'Hebron
Barcelona, , Spain
Clínica Dr. Quintero
Madrid, , Spain
Hs. Infanta Elena
Madrid, , Spain
Psykiatrisk klinik Umeå
Umeå, , Sweden
University Hospitals of Geneva
Geneva, , Switzerland
Cumbria Northumb, Tyne & Wear FT, Adult Psychiatry Dept
Newcastle upon Tyne, , United Kingdom
Tees Esk and Wear Valley foundation
York, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain more information on the study, click here/on this link
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MACS-2020-070101
Identifier Type: OTHER
Identifier Source: secondary_id
TAK-489-4004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.